Business Model & Revenue
bioAffinity Technologies operates primarily as a commercial-stage diagnostic company, generating revenue through the sale and processing of its proprietary CyPath Lung test. The test is a non-invasive flow cytometry-based diagnostic that analyzes sputum to identify early-stage lung cancer. By offering a less invasive alternative to traditional biopsies, the company targets the massive population of high-risk smokers and former smokers who require routine screening.
Revenue is generated on a per-test basis, with samples processed at the company's CLIA-certified laboratory. The business model benefits from high gross margins at scale, as the marginal cost of processing an additional sputum sample is relatively low compared to the reimbursement rate. Recently, the company discontinued unprofitable legacy services to focus entirely on the CyPath commercial rollout, resulting in a temporary top-line contraction in 2025 but a structurally healthier margin profile moving into 2026.
Financial Highlights
Full-Year Results
| Metric | FY 2025 | FY 2024 | YoY% |
|---|---|---|---|
| Revenue | $6.16M | $9.36M | -34.1% |
| Gross Profit | $2.10M | $3.50M | -40.0% |
| Gross Margin | 34.0% | 37.3% | -330 bps |
| Net Income | -$14.8M | -$12.1M | NM |
| Net Margin | -240% | -129% | NM |
| EPS | -$8.66 | -$6.10 | NM |
| Cash | $1.8M | $4.2M | -57.1% |
Quarterly Progression
| Quarter | Revenue | Net Income | EPS | Gross Margin |
|---|---|---|---|---|
| Q2 2026 | $1.51M | -$3.37M | -$0.64 | 42.0% |
| Q1 2026 | $1.10M | -$3.80M | -$0.75 | 39.5% |
| Q4 2025 | $1.66M | -$3.10M | -$0.19 | 36.1% |
| Q3 2025 | $1.55M | -$4.10M | -$0.82 | 35.5% |
Balance Sheet Snapshot
| Item | Amount |
|---|---|
| Cash & Equivalents | $2.43M |
| Total Debt | $0.00M |
| Total Equity | $1.15M |
| Shares Outstanding | 1.85M |
Management expects continued triple-digit volume growth for CyPath Lung through the second half of 2026.
Competitive Landscape
The non-invasive cancer diagnostic space is highly competitive, dominated by massive incumbents focused on liquid biopsies (blood tests) rather than sputum analysis. bioAffinity has carved out a distinct niche by analyzing the localized environment of the lungs directly.
- Exact Sciences (EXAS): The dominant force in non-invasive screening (Cologuard) currently expanding into multi-cancer early detection. EXAS has a massive sales force and deep institutional relationships, making them a formidable competitor for provider mindshare.
- Guardant Health (GH): A leader in liquid biopsies for cancer therapy selection and recurrence monitoring. Guardant is heavily capitalized but focuses primarily on blood-based cell-free DNA rather than sputum.
- Veracyte (VCYT): A genomic diagnostics company with a strong pulmonary portfolio, including the Percepta Nasal Swab. VCYT is the closest direct competitor in the lung nodule evaluation space.
Competitive Moats:
- Proprietary Methodology: The use of porphyrin to selectively bind to cancer cells in sputum creates a unique, highly targeted diagnostic approach that avoids the noise often found in blood-based liquid biopsies.
- Expanding IP Portfolio: Recent patent grants in Hong Kong and other international jurisdictions create a legal barrier to entry for localized sputum diagnostics in emerging markets.
- Pivotal Clinical Data: Published trials demonstrating high sensitivity and specificity in early-stage lung cancer validation build durable trust with pulmonologists.
Catalysts
- Reimbursement Code Assignment: Securing a specific PLA or CPT code from Medicare for the post-treatment surveillance indication would immediately unlock broader adoption.
- Q3 2026 Earnings Report: Confirmation that the 216% volume growth seen in Q2 was not an anomaly but a sustainable commercial inflection point.
- Asian Licensing Agreements: Following the Hong Kong IP update, any partnership or licensing deal to commercialize CyPath in the APAC region would serve as a major non-dilutive catalyst.
- Capital Raise Execution: Resolving the near-term cash overhang through a strategic investment or non-dilutive financing would remove the primary bear argument depressing the valuation.
Not financial advice. For informational purposes only. DYOR. Find alpha where nobody's looking.
Key Risks
- Cash burn rate of ≈$3.37M per quarter leaves only limited runway against $2.43M cash on hand, necessitating near-term dilution.
- Heavy reliance on a single diagnostic product (CyPath Lung) exposes the company to extreme concentration risk.
- Reimbursement landscape remains fragmented; failure to secure broad Medicare/Medicaid coverage could stall revenue growth.
- Nasdaq delisting risk remains a persistent overhang given the volatile nano-cap valuation history.
- Intense competition in the liquid biopsy and non-invasive cancer screening market from deep-pocketed incumbents like Exact Sciences.
Our Thesis
The market is fundamentally mispricing the transition of bioAffinity from an R&D-stage biotech into a commercial diagnostic operation. Expanding the CyPath Lung test into post-treatment surveillance effectively doubles their total addressable market beyond one-off preventative screening. The recent 216% volume surge in Q2 proves the underlying technology has tangible clinical utility. Furthermore, securing IP in Hong Kong paves the way for licensing agreements in Asia, which could provide non-dilutive capital injections without requiring BIAF to build an international salesforce from scratch.
Valuing a cash-burning nano-cap requires a forward-looking revenue multiple. Assuming the current trajectory holds, we model FY2027 revenue at $12.0M as surveillance testing augments initial screening volumes. Applying a conservative 4x EV/Sales multiple—a standard baseline for early-commercial diagnostic peers—yields an enterprise value of $48.0M. Adjusting for expected dilution (an estimated 3.0M fully diluted shares post-raise), we arrive at a 12-month price target of $16.00. The Speculative Buy rating reflects the binary outcome of bridging the funding gap to profitability.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.